Pharmosa Biopharm Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018
Period Ending	Feb '25 Feb 13, 2025	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018
Market Capitalization	7,848	10,314	7,055	-	-	-	Upgrade
Market Cap Growth	-18.69%	46.19%	-	-	-	-	Upgrade
Enterprise Value	6,358	9,330	6,778	-	-	-	Upgrade
Last Close Price	60.80	88.00	62.22	-	-	-	Upgrade
PE Ratio	-	1219.72	-	-	-	-	Upgrade
PS Ratio	148.58	32.79	-	-	-	-	Upgrade
PB Ratio	4.12	9.07	9.27	-	-	-	Upgrade
P/TBV Ratio	4.41	9.07	9.27	-	-	-	Upgrade
P/OCF Ratio	-	243.13	-	-	-	-	Upgrade
EV/Sales Ratio	125.84	29.67	-	-	-	-	Upgrade
EV/EBITDA Ratio	-	3121.44	-	-	-	-	Upgrade
Debt / Equity Ratio	0.06	0.13	0.03	0.07	0.31	-3.07	Upgrade
Debt / EBITDA Ratio	-	7.04	-	-	-	-	Upgrade
Asset Turnover	0.03	0.29	-	-	-	-	Upgrade
Quick Ratio	24.55	12.58	24.23	13.96	4.18	0.08	Upgrade
Current Ratio	25.20	13.02	24.65	14.39	4.31	0.11	Upgrade
Return on Equity (ROE)	-18.71%	0.89%	-41.24%	-54.73%	-103.22%	-	Upgrade
Return on Assets (ROA)	-11.52%	-0.17%	-24.49%	-28.67%	-35.08%	-72.37%	Upgrade
Return on Capital (ROIC)	-11.85%	-0.17%	-25.13%	-29.48%	-36.52%	-81.93%	Upgrade
Earnings Yield	-3.73%	0.08%	-3.78%	-	-	-	Upgrade
FCF Yield	-5.80%	-0.38%	-3.81%	-	-	-	Upgrade
Buyback Yield / Dilution	-13.07%	-15.09%	-16.02%	-78.34%	-27.94%	-61.72%	Upgrade
Total Shareholder Return	-13.07%	-15.09%	-16.02%	-78.34%	-27.94%	-61.72%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.